Cereno Scientific

Epitome Therapeutics

This biotechnology firm develops an epigenome editing platform for programmable gene expression to treat patients with rare genetic and metabolic disorders.

Gossamer Bio

This biopharmaceutical company develops inhaled therapies for patients suffering from pulmonary arterial hypertension and interstitial lung disease.

Cerenis Therapeutics Holding SA

This biopharmaceutical company develops high-density lipoprotein therapies to treat patients with cardiovascular and metabolic diseases, as well as renal and oncology conditions.

Chinook Therapeutics

This biopharmaceutical company develops precision medicines for patients with rare and severe chronic kidney diseases.

Oncopeptides AB

This biotech company develops targeted therapies for patients with difficult-to-treat hematological diseases, specifically focusing on multiple myeloma treatments.

Vicore Pharma

This clinical-stage biopharmaceutical company develops angiotensin II type 2 receptor agonists to treat patients with idiopathic pulmonary fibrosis and other rare lung diseases.

Marea Therapeutics

This biotechnology company develops medicines for cardiometabolic and cardioendocrine diseases using human genetic data for patients with unmet medical needs.

Scenic Biotech

This company develops disease-modifying small molecule therapeutics for patients with rare genetic and neurodegenerative disorders using its proprietary genetic modifier discovery platform.